Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)
Open Access
- 4 June 2024
- journal article
- review article
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 862-882
Abstract
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.Keywords
This publication has 135 references indexed in Scilit:
- Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination ChemotherapyMini-Reviews in Medicinal Chemistry, 2010
- Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA DamageMolecular Cell, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Flavopiridol in the treatment of chronic lymphocytic leukemiaCurrent Opinion in Oncology, 2007
- Cdk1: the dominant sibling of Cdk2Nature Cell Biology, 2005
- Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapySeminars in Oncology, 2002
- The Cell Cycle: A ReviewVeterinary Pathology, 1998
- Role of the p16 tumor suppressor gene in cancer.Journal of Clinical Oncology, 1998
- The Cell Cycle and Regulation of Cancer Cell GrowthAnnals of the New York Academy of Sciences, 1996
- Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.1995